MK-6194, Placebo for MK-6194
MK-6194-006
Phase 3 small_molecule active
Quick answer
MK-6194, Placebo for MK-6194 for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active